Table 1 Demographical and clinical features of the patients.

From: Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

Variables

ATLG + PTCy 25 (n = 29)

PTCy 50 (n = 41)

p

Age, years

37 (24.50)

40 (29.00)

0.502a

Gender (F/M)

14/15

19/22

0.873c

BMI

24.91 (5.27)

24.00 (7.92)

0.619a

Prior lines

1 (1.00)

1.00 (1.00)

0.162b

Leukemia subtypes

 AML

14 (48.3)

31 (75.6)

0.017c

 ALL

15 (51.7)

10 (24.4)

 

Donor age

34 (16.50)

32 (23.50)

0.729b

ECOG, 0/1

17/12

30/11

0.202c

Karnofksy score

100 (10)

100(10)

0.106b

HCT score

0 (1)

0 (1)

0.118b

aHCT score

1 (2)

1 (1)

0.172b

Transplant Intensity, RIC/MAC

3/26

13/28

0.036c

Donor compatibility

 MSD

21 (72.4)

29 (70.7)

 

 MUD

2 (6.9)

2 (4.9)

0.903c

 Unrelated 1 mismatch

2 (6.9)

2 (4.9)

 

 Haploidentical

4 (13.8)

8 (19.5)

 

CD34+ cell account, 106/kg

7.60 (2.05)

7.34 (1.90)

0.314a

Blood group incompatibility

   

 None

24 (82.8)

30 (73.2)

 

 Major

2 (6.9)

5 (12.2)

0.394c

 Minor

2 (6.9)

6 (14.6)

 

 Bidirectional

1 (3.4)

None

 

Pre-transplant hemoglobin, gr/dl

9.50 (1.95)

10.30 (1.60)

0.421a

Pre-transplant leukocyte, Cells/uL

3350 (3125)

4900 (3010)

0.028b

Pre-transplant neutrophil, Cells/uL

2340 (2625)

3300 (2850)

0.113b

Pre-transplant lymphocyte, Cells/uL

670 (995)

870 (810)

0.712b

Pre-transplant platelet, Cells/uL

124000 (201500)

173000 (83000)

0.211b

Pre-transplant LDH, U/L

242 (99)

186 (130.50)

0.188b

Pretransplant Ferritin, Microgram/L

1400 (1053)

946 (1235)

0.141b

  1. Continuous variables expressed as median and interquartile range; categorical variables were expressed as numbers and percentages.
  2. F/M Female/Male; BMI: Body Mass Index, ATLG Anti-T-lymphocyte globulin, BMI Body Mass Index, AML Acute Myeloid Leukemia, ALL Acute Lymphoblastic Leukemia, HCT Hematopoietic Cell Transplantation (HCT)-specific Comorbidity Index, aHCT Age adjusted Hematopoietic Cell Transplantation (HCT)-specific Comorbidity Index, RIC Reduced-Intensity Conditioning, MAC Myeloablative Conditioning, MSD Matched Sibling Donor, MUD Matched Unrelated Donor, HLA Humal Leukocyte Antigen, LDH Lactate Dehydrogenase.
  3. aIndependent Sample T test.
  4. bMann Whitney U.
  5. cPearson Chi Square.
Back to article page